Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
Commentary|Articles|June 9, 2026
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
Author(s)Kyle Doherty
Fact checked by: Courtney Flaherty, Tracy Ann Politowicz
ASCO 2026 genitourinary experts unpack key prostate and bladder cancer data, revealing practice-changing takeaways and what they mean for patient care.
Advertisement
Advertisement
OncLive® connected with genitourinary oncology experts at the
Related to this article
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.
Katie S. Murray, DO, discusses how efficacy, toxicity, patient preferences, and treatment logistics guide BCG-unresponsive NMIBC care.
Vignesh T. Packiam, MD, reviews why improved BCG outcomes support its first-line use, with gemcitabine/docetaxel as a BCG-sparing option.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Advertisement
Advertisement